{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-117214","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.406905+00:00","generated_at":"2026-05-30T00:59:34.453209+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Acurx Pharma Q3 net loss $2.8M; cash $5.8M; advancing ibezapolstat Phase 3","bullets":["Net loss $2.8M ($0.17/diluted share) vs $3.1M ($0.24) in Q3 2023; nine-month net loss $11.3M.","Cash $5.8M at Sep 30, 2024, down from $7.5M at Dec 31, 2023; raised $1.6M gross via ATM.","Requested FDA CMC meeting to start Phase 3 for ibezapolstat; USPTO patent granted through 2042.","R&D expenses $1.2M (Q3) vs $1.3M prior year; G&A $1.6M vs $1.8M prior year."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-117214","json":"https://secwatch.observer/filing/0001104659-24-117214.json","markdown":"https://secwatch.observer/filing/0001104659-24-117214.md","text":"https://secwatch.observer/filing/0001104659-24-117214.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465924117214/0001104659-24-117214-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465924117214/tm2428175d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:59:34.453209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}